Thismedicationis used along with diet changes for long-term treatment of a certain inherited disorder (phenylketonuria-PKU). It helps remove a certain chemical (phenylalanine) from the body. Too much phenylalanine in the body can causebrain damage. ...
L-3,4-dihydroxyphenylalanine (L-DOPA) reduces symptoms of Parkinson's disease (PD), but suffers from serious side effects on long-term use. Melatonin (10–... A Naskar,V Prabhakar,R Singh,... - 《Journal of Pineal Research》 被引量: 19发表: 2015年 加载更多来源...
The most promising results have been from experiments using recombinant adeno-associated virus vector in which long-term correction without adverse effects has been reported in the mouse model (PKU enu2). However, there are some limitations to this approach for clinical use including the requirement...
Side effectsWhen taken by mouth: L-phenylalanine is LIKELY SAFE for most people when taken in amounts commonly found in foods. L-phenylalanine is POSSIBLY SAFE when taken as medicine, short-term. D-phenylalanine is POSSIBLY SAFE when used as a single dose of up to 10 grams. There isn't...
disorder and other psychiatric disorders in PAH deficiency and to assess the response of PAH patients to standard pharmacological or behavioral interventions.87–89 Additional negative effects have emerged in individuals affected with PAH deficiency and their families who have been followed long term. The...
Long-Term Treatment and Diagnosis of Tetrahydrobiopterin-Responsive Hyperphenylalaninemia with a Mutant Phenylalanine Hydroxylase Gene HARUO SHINTAKU, SHIGEO KURE, TOSHIHIRO OHURA, YOSHIYUKI OKANO, MISAO OHWADA, NARUJI SUGIYAMA, NOBUO SAKURA, ICHIRO YOSHIDA, MAKOTO YOSHINO, YOICHI MATSUBARA, KEN SUZUKI, ...
Nevertheless, the long-term treatment of HAART exhibits severe limitations such as the high costs, the development of drug resistance [3,4], drug-drug interactions, and a variety of side effects due to serious toxicity [5]. As a result, there is still an urgent and desirable requirement ...
The term “prodrug” refers to a precursor of a pharmaceutically active compound wherein the precursor itself may or may not be pharmaceutically active but, upon administration, will be converted, either metabolically or otherwise, into the pharmaceutically active compound or drug of interest. For ex...
These findings suggest that the cumulative recovery of 5 to 6% is also sufficient for maintaining serum phenylalanine level (0.12 mM) in patients with PAH deficiency and that our test may be potentially useful for determining the optimal dosage of BH4 for long-term medication of BH4-responsive ...
Gene ontology (GO)-term enrichment analysis was done using ToppGene61. Phosphoproteome data was downloaded from PDC commons (https://pdc.cancer.gov), and a similar analysis as to proteome analysis was undertaken using a customized PERL script....